Keywords: AstraZeneca, Onglyza, Merck & Co, Januvia, EC approval
AstraZeneca’s potential blockbuster diabetes drug Onglyza approved by EC
Article | 06 October 2009
The European Commission has granted marketing authorization for Anglo-Swedish drug major AstraZeneca and US partner Bristol-Myers Squibb’s Onglyza (saxagliptin) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
